WW — WW International, Inc.

Summary of WW (WeightWatchers) Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total Revenue: $163 million, down 12% year-over-year, driven by a 32% increase in clinical revenue but a 17% decline in behavioral revenue.
• Adjusted EBITDA: $18 million, with a margin of 11.1%.
• Adjusted Gross Margin: 74.4%, slightly down from Q3 due to increased clinical staffing costs.
• End-of-Period Clinical Subscribers: 130,000, with expectations to reach approximately 200,000 by the end of Q1 2026, indicating nearly 100% year-over-year growth.
• End-of-Period Behavioral Subscribers: 2.6 million, a decline of approximately 26% year-over-year.
• Average Revenue Per User (ARPU): Increased 8% year-over-year to $18.73, with clinical ARPU over four times higher than behavioral ARPU.

2. Strategic Updates and Business Highlights:

• WeightWatchers is transitioning from a behavioral subscription model to an integrated weight health ecosystem that includes medication access and clinical care.
• The company has reduced its legacy debt by over 70% post-Chapter 11 reorganization, allowing for increased investment in growth initiatives.
• The launch of the GLP-1 Success program has shown promising results, with members losing 30% more weight on average compared to competitors.
• Marketing efforts have successfully increased brand awareness, particularly for the Med+ offering, with 50% of new Med+ members being new to the WeightWatchers brand.
• The mobile app has been relaunched with new features, including an AI body scanner and personalized modes.

3. Forward Guidance and Outlook:

• For fiscal year 2026, revenue is expected to range from $620 million to $635 million, with adjusted EBITDA projected between $105 million and $115 million.
• The company anticipates a seasonal decline in demand post-peak season and plans to rebalance marketing spend between behavioral and clinical offerings.
• Cash flow in Q1 is expected to be negative due to peak marketing investments, but the company aims to manage liquidity effectively throughout the year.

4. Bad News, Challenges, or Points of Concern:

• The behavioral segment faces ongoing secular headwinds, with subscriber numbers declining significantly.
• The strategic focus on the Med+ offering may lead to further revenue headwinds in the core behavioral business.
• The transition from a legacy model to a new integrated approach presents risks, particularly in maintaining member engagement and retention during this period of change.
• The competitive landscape is shifting rapidly with the rise of GLP-1 medications, which may disrupt traditional behavioral models.

5. Notable Q&A Insights:

• Demand for weight loss medications, particularly the Wegovy pill, is increasing, with new forms of medication lowering barriers for potential members.
• The company is seeing a demographic shift with younger members joining and a notable increase in lapsed members returning.
• The B2B initiative is gaining traction, though it remains a small percentage of total revenue; partnerships with companies like UnitedHealth are being expanded.
• The company is focused on long-term member outcomes rather than solely increasing subscriber numbers, emphasizing the importance of integrated support systems.

Overall, WeightWatchers is navigating a significant transformation in its business model while facing challenges in its traditional behavioral segment. The company is optimistic about its future, particularly with the integration of clinical offerings and the potential for growth in the GLP-1 space.